Immuno-Oncology Market
Immuno-oncology Market Study by Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus, and Others from 2024 to 2034
Analysis of Immuno-oncology Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Immuno-oncology Market Outlook from 2024 to 2034)
The global immuno-oncology market size is estimated to have a value of US$ 24.17 billion in 2024. The market is expected to register a stirring CAGR of 16.5% from 2024 to 2034. By the end of the forecast period, the market size is expected to be worth US$ 111.64 billion.
The global rise in cancer patients is highlighting the need for cancer treatments. Immuno-oncology is thus being reverted to for handling cancer patients. Preventive healthcare measures ensure cancer is being detected at early stages, and thus, there is more room for immuno-oncology to do its work.
Key Market Growth Drivers
New methods of treatment ensure that immuno-oncology is an ever-evolving field. Newer forms of treatment, like tumor-infecting viruses and cytokines, are ensuring that the market is not fixated on select forms of treatment. The positive response to the innovative treatments is further boosting the image of immuno-oncology.
In a bid to cope with the rise in cancer patients and eventually curtail death numbers, the regulatory bodies are favoring immuno-oncology. New drugs and treatment methods are more frequently receiving approvals from prominent regulatory bodies like the United States Food & Drug Administration (FDA). Thus, the influx of new products in the market is rapid, and the demand for immuno-oncology keeps flowing.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 24.17 billion |
| Forecasted Market Value (2034F) | US$ 111.64 billion |
| Global Market Growth Rate (2024 to 2034) | 16.5% CAGR |
| Immune Checkpoint Inhibitors Segment Growth Rate (2024 to 2034) | 16.8% |
| Melanoma Segment Growth Rate (2024 to 2034) | 15.6% |
| North America Market Share (2024) | 71.0% |
| East Asia Market Share (2024) | 12.5% |
| Key Companies Profiled | Bristol Myers Squibb Company; Novartis AG; F. Hoffmann-LA Roche Ltd.; Merck & Co., Inc.; GSK Plc.; Eli Lilly and Company; Fresenius Kabi AG; Pfizer Inc.; AbbVie Inc.; Genentech Inc.; Sanofi; AstraZeneca |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Factors Have Driven the Global Surge in Immuno-oncology Demand?
“Growing Confidence in the Ability of the Human Immune System Sees Immuno-oncology Treatment Find Greater Acceptance”
The focus of immuno-oncology is on bringing out the power of the immune system in combatting cancer cells. Therefore, immuno-oncology emphasizes the human immune system. With positive new revelations about the immune system, including its ability to fight cancer cells, there is a growing positive outlook towards immuno-oncology.
“Immunotherapy Being Used in Combination with Other Cancer Treatments is Bolstering the Demand for Immuno-oncology”
While the traditional market strategy would be to see chemotherapy and other cancer treatments as competitors to immuno-oncology, doctors often use a combination of immuno-oncology with other treatments. The severity of the cancers affecting the human body is sometimes such that one mode of treatment is not enough.
Cancer is still a key subject of study and research, and as new methods of treatment get developed, doctors are utilizing the best possible combination in treatment. Thus, the market for immuno-oncology is growing hand-in-hand with other forms of cancer treatments like chemotherapy.
Which Factors Present Challenges to the Expansion of the Immuno-oncology Market?
“High Cost of Treatment and Manufacturing Difficulties Have the Potential to Slow Down the Growth of the Market”
Cancer treatments have earned a reputation for being costly. Immuno-oncology is no different, as the cost of drugs and treatment is not insignificant. Thus, a lot of people are not able to afford the treatment.
Immuno-oncology is a fast-developing market, with the rate of newer drugs and treatments being introduced rapidly. However, manufacturers often face difficulty in procuring the required amount of raw materials as other sections in the healthcare sector have the propensity to lag behind the latest developments. Thus, there are often difficulties with manufacturing. However, despite the challenges, the overall outlook for the market over the forecast period is bright.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
East Asia is a hotbed for developments in the healthcare sector. The immuno-oncology market, too, is reaping the benefits of the region's growing healthcare sector. For 2024, the value of the market in East Asia is estimated to be US$ 3.01 billion, for a market share of 12.5%.
The market is expected to progress at an enthralling rate in East Asia from 2024 to 2034, with a CAGR of 15.2%. By 2034, it is projected that the market value for East Asia is likely to jump to US$ 12.37 billion, with a market share of 11.1%.
The North America immuno-oncology market is dominating globally. Even though, over the forecast period, the share of the region in the global market is projected to reduce, North America is expected to continue being a fertile ground for the immuno-oncology industry. For 2024, the market share for North America is projected to be 71.0%, with a market value of US$ 17.16 billion. The market is expected to register a remarkable CAGR of 13.9% in North America for the forecast period. By 2034, the market value in North America is anticipated to have shot up to US$ 62.97 billion, with a market share of 56.4%.
What Makes China Such a Promising Country for the Immuno-oncology Market?
“Government Encouragement Propels the Research and Development of Immuno-oncology Treatments in China”
China is filled with promise for immuno-oncology, and the 2024 market valuation is estimated to be US$ 1.68 billion. The immuno-oncology market in China is expected to register an impressive CAGR of 15.2% over the forecast period, at the end of which, the market value for the country is projected to hit US$ 6.96 billion.
The government in China has given research relating to cancer treatment a prominent place in its health policy. Thus, the government is positive about the development of novel immuno-oncology treatments. Research work in the field is also encouraged.
Why is Japan Emerging as a Lucrative Country for the Immuno-oncology Market?
“Japan Enabling the Introduction of Novel Drugs and Forms of Treatment in the Immuno-oncology Field”
The progress of the immuno-oncology market in Japan is anticipated to be even faster than in China, making it one of the premier countries for the industry. The 2024 market valuation for the country is US$ 0.77 billion. From 2024 to 2034, the market is expected to progress at a stellar rate in Japan, with a CAGR of 15.5%. By 2034, the market valuation is expected to reach US$ 3.26 billion.
Japan’s aging population contributes to cancer rates increasing in the country. To get control over the rise in people affected by cancer, Japanese regulatory bodies are approving newer drugs and treatments with enthusiasm. For example, in 2023, the Japanese Patent Office granted a patent to the immuno-oncology company Imugene for its PD1-Vaxx candidate.
Category-wise Insights
Based on therapy type, immune checkpoint inhibitors are the leaders in the market. For 2024, immune checkpoint inhibitors are expected to account for an overwhelming 91.4% of the market share. Immune system modulators are a distant second, expected to contribute to 3.8% of the market share in 2024. Based on the therapeutic area, melanoma is the leader, with an estimated 36.9% of the market share in 2024. Lung cancer is not far behind, with an estimated market share of 31.7% in 2024.
Why are Immune Checkpoint Inhibitors the Top Form of Therapy in Immuno-oncology?
“Checkpoint Inhibitors’ Positive Results are Leading to More Doctors Relying on the Treatment Method”
Checkpoint inhibitors are the predominant type of therapy in immuno-oncology. For 2024, checkpoint inhibitors are expected to contribute to a mammoth 91.4% of the market share. The product is expected to progress at a CAGR of 16.8% over the forecast period. By 2034, checkpoint inhibitors’ market share is expected to have grown even further to 93.7%.
Checkpoint inhibitors have shown positive results even in the relatively short amount of time the treatment has been available. Thus, doctors are not hesitant about administering the form of treatment.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Collaboration between market players is a common sighting in the immuno-oncology landscape. By means of collaborations, the companies hope to fuse the technological capabilities of different organizations.
The partnerships extend across international borders. Many Western companies are teaming up with their Asian counterparts to explore opportunities in the global market. The development and authorization of new drugs and treatments is also a common concern in the market. Some of the key companies in the market are Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-LA Roche Ltd., Merck & Co., Inc., GSK Plc., Eli Lilly and Company, Fresenius Kabi AG, Pfizer Inc., AbbVie Inc., Genentech Inc., Sanofi, and AstraZeneca.
Recent Developments in the Market are:
- In December 2023, Elpiscience Biopharma signed an agreement with Astellas Pharma. The companies will jointly carry out research programs on cancer treatment, with Elpiscience in for monetary rewards of over US$ 1.7 billion in case milestones are met.
- In September 2023, South Korean player GI Innovation inked a deal with American clinical trial data solution provider Medidata Solutions. The South Korean company hopes to leverage the American’s AI and big data capabilities for the development of two new drugs- GI-101 and GI 102.
- In May 2023, American startup KSQ Therapeutics and Japanese enterprise Takeda expanded the scope of their partnership. KSQ Therapeutics increased its investment in the Japanese player, with further monetary rewards should their common targets be met.
Segmentation of Immuno-oncology Market Research
-
By Therapy Type:
- Immune Checkpoint Inhibitors
- Immune System Modulators
- Cancer Vaccines
- Oncolytic Virus
- Others
-
By Therapeutic Area:
- Melanoma
- Lung Cancer
- Blood Cancers
- Renal Cell Carcinoma
- Prostate Cancer
- Bladder Cancer
- Other Cancers
-
By End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
-
By Region:
- North America
- Europe
- Latin America
- East Asia
- South Asia & Oceania
- The Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Background
- 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
- 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Type
- 5.1. Immune Cell Therapy (CAR-T)
- 5.2. Monoclonal Antibodies
- 5.3. Checkpoint Inhibitors
- 5.4. Cytokines
- 5.5. Cancer Vaccines
- 5.6. Others
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Targets
- 6.1. IDO1i
- 6.2. Oncolytic virus
- 6.3. STING agonist
- 6.4. TLR agonist
- 6.5. TIL
- 6.6. MEKi
- 6.7. TIGIT
- 6.8. CPI
- 6.9. GITR agonist
- 6.10. TGF-b trap
- 6.11. LAG-3
- 6.12. Others
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
- 7.1. Malignant Tumors
- 7.2. Benign Tumors
- 7.3. Others
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End Users
- 8.1. Hospitals
- 8.2. Specialty Clinics
- 8.3. Others
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
- 9.1. Hospital Pharmacy
- 9.2. Retail Pharmacy
- 9.3. Others
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. South Asia and Pacific
- 10.6. East Asia
- 10.7. Middle East and Africa
- 11. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 12. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 13. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 14. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 16. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 17. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
- 18. Key Countries Market Analysis
- 19. Market Structure Analysis
- 20. Competition Analysis
- 20.1. Bristol Myers Squibb Company
- 20.2. Novartis AG
- 20.3. F. Hoffmann-LA Roche Ltd.
- 20.4. Merck & Co., Inc.
- 20.5. GSK Plc.
- 20.6. Eli Lilly and Company
- 20.7. Fresenius Kabi AG
- 20.8. Pfizer Inc.
- 20.9. AbbVie Inc.
- 20.10. Genentech Inc.
- 20.11. Sanofi
- 21. Assumptions & Acronyms Used
- 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 2: Global Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 3: Global Market Value (US$ Million) Forecast by Targets, 2019 to 2034
Table 4: Global Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 5: Global Market Value (US$ Million) Forecast by End Users, 2019 to 2034
Table 6: Global Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 7: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 8: North America Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 9: North America Market Value (US$ Million) Forecast by Targets, 2019 to 2034
Table 10: North America Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 11: North America Market Value (US$ Million) Forecast by End Users, 2019 to 2034
Table 12: North America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 13: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 14: Latin America Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 15: Latin America Market Value (US$ Million) Forecast by Targets, 2019 to 2034
Table 16: Latin America Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 17: Latin America Market Value (US$ Million) Forecast by End Users, 2019 to 2034
Table 18: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 19: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 20: Western Europe Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 21: Western Europe Market Value (US$ Million) Forecast by Targets, 2019 to 2034
Table 22: Western Europe Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 23: Western Europe Market Value (US$ Million) Forecast by End Users, 2019 to 2034
Table 24: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 25: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 26: Eastern Europe Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 27: Eastern Europe Market Value (US$ Million) Forecast by Targets, 2019 to 2034
Table 28: Eastern Europe Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 29: Eastern Europe Market Value (US$ Million) Forecast by End Users, 2019 to 2034
Table 30: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 31: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 32: South Asia and Pacific Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 33: South Asia and Pacific Market Value (US$ Million) Forecast by Targets, 2019 to 2034
Table 34: South Asia and Pacific Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 35: South Asia and Pacific Market Value (US$ Million) Forecast by End Users, 2019 to 2034
Table 36: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 37: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 38: East Asia Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 39: East Asia Market Value (US$ Million) Forecast by Targets, 2019 to 2034
Table 40: East Asia Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 41: East Asia Market Value (US$ Million) Forecast by End Users, 2019 to 2034
Table 42: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 43: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 44: Middle East and Africa Market Value (US$ Million) Forecast by Type, 2019 to 2034
Table 45: Middle East and Africa Market Value (US$ Million) Forecast by Targets, 2019 to 2034
Table 46: Middle East and Africa Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 47: Middle East and Africa Market Value (US$ Million) Forecast by End Users, 2019 to 2034
Table 48: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value (US$ Million) by Type, 2024 to 2034
Figure 2: Global Market Value (US$ Million) by Targets, 2024 to 2034
Figure 3: Global Market Value (US$ Million) by Indication, 2024 to 2034
Figure 4: Global Market Value (US$ Million) by End Users, 2024 to 2034
Figure 5: Global Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 6: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 7: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 8: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 9: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 10: Global Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 11: Global Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 12: Global Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 13: Global Market Value (US$ Million) Analysis by Targets, 2019 to 2034
Figure 14: Global Market Value Share (%) and BPS Analysis by Targets, 2024 to 2034
Figure 15: Global Market Y-o-Y Growth (%) Projections by Targets, 2024 to 2034
Figure 16: Global Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 17: Global Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 18: Global Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 19: Global Market Value (US$ Million) Analysis by End Users, 2019 to 2034
Figure 20: Global Market Value Share (%) and BPS Analysis by End Users, 2024 to 2034
Figure 21: Global Market Y-o-Y Growth (%) Projections by End Users, 2024 to 2034
Figure 22: Global Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 23: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 24: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 25: Global Market Attractiveness by Type, 2024 to 2034
Figure 26: Global Market Attractiveness by Targets, 2024 to 2034
Figure 27: Global Market Attractiveness by Indication, 2024 to 2034
Figure 28: Global Market Attractiveness by End Users, 2024 to 2034
Figure 29: Global Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 30: Global Market Attractiveness by Region, 2024 to 2034
Figure 31: North America Market Value (US$ Million) by Type, 2024 to 2034
Figure 32: North America Market Value (US$ Million) by Targets, 2024 to 2034
Figure 33: North America Market Value (US$ Million) by Indication, 2024 to 2034
Figure 34: North America Market Value (US$ Million) by End Users, 2024 to 2034
Figure 35: North America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 36: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 37: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 38: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 39: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 40: North America Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 41: North America Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 42: North America Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 43: North America Market Value (US$ Million) Analysis by Targets, 2019 to 2034
Figure 44: North America Market Value Share (%) and BPS Analysis by Targets, 2024 to 2034
Figure 45: North America Market Y-o-Y Growth (%) Projections by Targets, 2024 to 2034
Figure 46: North America Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 47: North America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 48: North America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 49: North America Market Value (US$ Million) Analysis by End Users, 2019 to 2034
Figure 50: North America Market Value Share (%) and BPS Analysis by End Users, 2024 to 2034
Figure 51: North America Market Y-o-Y Growth (%) Projections by End Users, 2024 to 2034
Figure 52: North America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 53: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 54: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 55: North America Market Attractiveness by Type, 2024 to 2034
Figure 56: North America Market Attractiveness by Targets, 2024 to 2034
Figure 57: North America Market Attractiveness by Indication, 2024 to 2034
Figure 58: North America Market Attractiveness by End Users, 2024 to 2034
Figure 59: North America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 60: North America Market Attractiveness by Country, 2024 to 2034
Figure 61: Latin America Market Value (US$ Million) by Type, 2024 to 2034
Figure 62: Latin America Market Value (US$ Million) by Targets, 2024 to 2034
Figure 63: Latin America Market Value (US$ Million) by Indication, 2024 to 2034
Figure 64: Latin America Market Value (US$ Million) by End Users, 2024 to 2034
Figure 65: Latin America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 66: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 67: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 68: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 69: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 70: Latin America Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 71: Latin America Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 72: Latin America Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 73: Latin America Market Value (US$ Million) Analysis by Targets, 2019 to 2034
Figure 74: Latin America Market Value Share (%) and BPS Analysis by Targets, 2024 to 2034
Figure 75: Latin America Market Y-o-Y Growth (%) Projections by Targets, 2024 to 2034
Figure 76: Latin America Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 77: Latin America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 78: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 79: Latin America Market Value (US$ Million) Analysis by End Users, 2019 to 2034
Figure 80: Latin America Market Value Share (%) and BPS Analysis by End Users, 2024 to 2034
Figure 81: Latin America Market Y-o-Y Growth (%) Projections by End Users, 2024 to 2034
Figure 82: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 83: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 84: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 85: Latin America Market Attractiveness by Type, 2024 to 2034
Figure 86: Latin America Market Attractiveness by Targets, 2024 to 2034
Figure 87: Latin America Market Attractiveness by Indication, 2024 to 2034
Figure 88: Latin America Market Attractiveness by End Users, 2024 to 2034
Figure 89: Latin America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 90: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 91: Western Europe Market Value (US$ Million) by Type, 2024 to 2034
Figure 92: Western Europe Market Value (US$ Million) by Targets, 2024 to 2034
Figure 93: Western Europe Market Value (US$ Million) by Indication, 2024 to 2034
Figure 94: Western Europe Market Value (US$ Million) by End Users, 2024 to 2034
Figure 95: Western Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 96: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 97: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 98: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 99: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 100: Western Europe Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 101: Western Europe Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 102: Western Europe Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 103: Western Europe Market Value (US$ Million) Analysis by Targets, 2019 to 2034
Figure 104: Western Europe Market Value Share (%) and BPS Analysis by Targets, 2024 to 2034
Figure 105: Western Europe Market Y-o-Y Growth (%) Projections by Targets, 2024 to 2034
Figure 106: Western Europe Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 107: Western Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 108: Western Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 109: Western Europe Market Value (US$ Million) Analysis by End Users, 2019 to 2034
Figure 110: Western Europe Market Value Share (%) and BPS Analysis by End Users, 2024 to 2034
Figure 111: Western Europe Market Y-o-Y Growth (%) Projections by End Users, 2024 to 2034
Figure 112: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 113: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 114: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 115: Western Europe Market Attractiveness by Type, 2024 to 2034
Figure 116: Western Europe Market Attractiveness by Targets, 2024 to 2034
Figure 117: Western Europe Market Attractiveness by Indication, 2024 to 2034
Figure 118: Western Europe Market Attractiveness by End Users, 2024 to 2034
Figure 119: Western Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 120: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 121: Eastern Europe Market Value (US$ Million) by Type, 2024 to 2034
Figure 122: Eastern Europe Market Value (US$ Million) by Targets, 2024 to 2034
Figure 123: Eastern Europe Market Value (US$ Million) by Indication, 2024 to 2034
Figure 124: Eastern Europe Market Value (US$ Million) by End Users, 2024 to 2034
Figure 125: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 126: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 127: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 128: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 129: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 130: Eastern Europe Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 131: Eastern Europe Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 132: Eastern Europe Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 133: Eastern Europe Market Value (US$ Million) Analysis by Targets, 2019 to 2034
Figure 134: Eastern Europe Market Value Share (%) and BPS Analysis by Targets, 2024 to 2034
Figure 135: Eastern Europe Market Y-o-Y Growth (%) Projections by Targets, 2024 to 2034
Figure 136: Eastern Europe Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 137: Eastern Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 138: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 139: Eastern Europe Market Value (US$ Million) Analysis by End Users, 2019 to 2034
Figure 140: Eastern Europe Market Value Share (%) and BPS Analysis by End Users, 2024 to 2034
Figure 141: Eastern Europe Market Y-o-Y Growth (%) Projections by End Users, 2024 to 2034
Figure 142: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 143: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 144: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 145: Eastern Europe Market Attractiveness by Type, 2024 to 2034
Figure 146: Eastern Europe Market Attractiveness by Targets, 2024 to 2034
Figure 147: Eastern Europe Market Attractiveness by Indication, 2024 to 2034
Figure 148: Eastern Europe Market Attractiveness by End Users, 2024 to 2034
Figure 149: Eastern Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 150: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 151: South Asia and Pacific Market Value (US$ Million) by Type, 2024 to 2034
Figure 152: South Asia and Pacific Market Value (US$ Million) by Targets, 2024 to 2034
Figure 153: South Asia and Pacific Market Value (US$ Million) by Indication, 2024 to 2034
Figure 154: South Asia and Pacific Market Value (US$ Million) by End Users, 2024 to 2034
Figure 155: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 156: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 157: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 158: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 159: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 160: South Asia and Pacific Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 161: South Asia and Pacific Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 162: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 163: South Asia and Pacific Market Value (US$ Million) Analysis by Targets, 2019 to 2034
Figure 164: South Asia and Pacific Market Value Share (%) and BPS Analysis by Targets, 2024 to 2034
Figure 165: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Targets, 2024 to 2034
Figure 166: South Asia and Pacific Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 167: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 168: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 169: South Asia and Pacific Market Value (US$ Million) Analysis by End Users, 2019 to 2034
Figure 170: South Asia and Pacific Market Value Share (%) and BPS Analysis by End Users, 2024 to 2034
Figure 171: South Asia and Pacific Market Y-o-Y Growth (%) Projections by End Users, 2024 to 2034
Figure 172: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 173: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 174: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 175: South Asia and Pacific Market Attractiveness by Type, 2024 to 2034
Figure 176: South Asia and Pacific Market Attractiveness by Targets, 2024 to 2034
Figure 177: South Asia and Pacific Market Attractiveness by Indication, 2024 to 2034
Figure 178: South Asia and Pacific Market Attractiveness by End Users, 2024 to 2034
Figure 179: South Asia and Pacific Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 180: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 181: East Asia Market Value (US$ Million) by Type, 2024 to 2034
Figure 182: East Asia Market Value (US$ Million) by Targets, 2024 to 2034
Figure 183: East Asia Market Value (US$ Million) by Indication, 2024 to 2034
Figure 184: East Asia Market Value (US$ Million) by End Users, 2024 to 2034
Figure 185: East Asia Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 186: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 187: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 188: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 189: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 190: East Asia Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 191: East Asia Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 192: East Asia Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 193: East Asia Market Value (US$ Million) Analysis by Targets, 2019 to 2034
Figure 194: East Asia Market Value Share (%) and BPS Analysis by Targets, 2024 to 2034
Figure 195: East Asia Market Y-o-Y Growth (%) Projections by Targets, 2024 to 2034
Figure 196: East Asia Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 197: East Asia Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 198: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 199: East Asia Market Value (US$ Million) Analysis by End Users, 2019 to 2034
Figure 200: East Asia Market Value Share (%) and BPS Analysis by End Users, 2024 to 2034
Figure 201: East Asia Market Y-o-Y Growth (%) Projections by End Users, 2024 to 2034
Figure 202: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 203: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 204: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 205: East Asia Market Attractiveness by Type, 2024 to 2034
Figure 206: East Asia Market Attractiveness by Targets, 2024 to 2034
Figure 207: East Asia Market Attractiveness by Indication, 2024 to 2034
Figure 208: East Asia Market Attractiveness by End Users, 2024 to 2034
Figure 209: East Asia Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 210: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 211: Middle East and Africa Market Value (US$ Million) by Type, 2024 to 2034
Figure 212: Middle East and Africa Market Value (US$ Million) by Targets, 2024 to 2034
Figure 213: Middle East and Africa Market Value (US$ Million) by Indication, 2024 to 2034
Figure 214: Middle East and Africa Market Value (US$ Million) by End Users, 2024 to 2034
Figure 215: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 216: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 217: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 218: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 219: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 220: Middle East and Africa Market Value (US$ Million) Analysis by Type, 2019 to 2034
Figure 221: Middle East and Africa Market Value Share (%) and BPS Analysis by Type, 2024 to 2034
Figure 222: Middle East and Africa Market Y-o-Y Growth (%) Projections by Type, 2024 to 2034
Figure 223: Middle East and Africa Market Value (US$ Million) Analysis by Targets, 2019 to 2034
Figure 224: Middle East and Africa Market Value Share (%) and BPS Analysis by Targets, 2024 to 2034
Figure 225: Middle East and Africa Market Y-o-Y Growth (%) Projections by Targets, 2024 to 2034
Figure 226: Middle East and Africa Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 227: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 228: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 229: Middle East and Africa Market Value (US$ Million) Analysis by End Users, 2019 to 2034
Figure 230: Middle East and Africa Market Value Share (%) and BPS Analysis by End Users, 2024 to 2034
Figure 231: Middle East and Africa Market Y-o-Y Growth (%) Projections by End Users, 2024 to 2034
Figure 232: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 233: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 234: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 235: Middle East and Africa Market Attractiveness by Type, 2024 to 2034
Figure 236: Middle East and Africa Market Attractiveness by Targets, 2024 to 2034
Figure 237: Middle East and Africa Market Attractiveness by Indication, 2024 to 2034
Figure 238: Middle East and Africa Market Attractiveness by End Users, 2024 to 2034
Figure 239: Middle East and Africa Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 240: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the Leading Therapy Type in the Immuno-oncology Market?
Immune checkpoint inhibitors are the leading type of therapy in the market, with an expected market share of 91.4% in 2024.
What is the Sales Outlook for Immuno-Oncology in 2024?
The sales outlook for immuno-oncology is likely to be valued at US$ 24.17 billion in 2024.
What is the Demand Forecast for Immuno-Oncology for the Decade?
Demand for immuno-oncology is projected to reach a market value of US$ 111.64 billion by the end of 2034.
What is the Adoption Growth Projection for Immuno-Oncology?
Adoption of immuno-oncology is projected to rise at a CAGR of 16.5% through 2034.
What are the Brands in the Immuno-oncology Market?
Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-LA Roche Ltd., and Merck & Co., Inc. are some of the prominent brands in the immuno-oncology market.
Immuno-Oncology Market